Translational Longevity Summit 2026
Translational Longevity Summit 2026 · Harvard Enterprise Research Campus, Boston · October 7–11, 2026Measure biological age. Do not assert it.
Five days at Harvard’s Enterprise Research Campus where longevity science has to survive contact with the clinic. We are Premier Sponsor: Hans Vink presents on the Sunday, and you can have your own microvasculature measured at our stand any day of the week.
Measure. Restore. Verify.Providing clinicians with the tools to measure, restore and verify microvascular health.
We are the Summit’s Premier Sponsor
Premier is the organiser’s highest sponsorship level, and there is one practical reason we took it: it comes with a full session on the programme rather than a booth and a logo. The point of being at a translational meeting is to be argued with by people who read the papers, and that happens on the programme, not in the hall.
A full session on the programme
Hans Vink presents a solo 30-minute session on Sunday 11 October — the Summit’s vascular slot. Speaking positions are reviewed by the programme committee, which declines product pitches; this is a methodology talk.
A stand across all five days
The Exhibitor Hall at 1 Milestone Place is open throughout, with traffic concentrated around breaks, lunches and poster sessions. We are measuring the whole time.
Hospitality
Premier is the only level carrying host status for a lunch or cocktail occasion, with podium recognition. Details of ours will be confirmed here nearer the Summit.
Ten full-access passes
Premier includes ten complimentary tickets covering all sessions, meals and materials. If you work with us and want to be in the room, ask — while they last.
Sponsorship levels and entitlements are the organiser’s, published at translationallongevity.com. Speaking positions at every level are subject to programme committee review.
The programme
Five days at Harvard’s Enterprise Research Campus
Six scientific tracks running across five days, and you do not have to take all of it — the organisers sell a one-to-three-day Flexi-Pass alongside the full pass. Below is each day as the organisers describe it, and what we are doing that day. Our stand is open throughout.
Wednesday October 7, 2026
A cross-border collaboration opens the Summit, as the Healthspan Action Coalition and the Cure Alliance join leading Italian organisations including the Bicocca Foundation, with Camillo Ricordi, MD and Giovanna Iannantuoni, PhD among the voices. David Barzilai, MD, PhD, DipABLM gives the day’s keynote on turning the age wave into opportunity, and patient-advocacy voices including Sabrina Cohen and Anne Marie Miller close the day.
On the programme
Welcome Reception at the Atlas Hotel, opening keynote and the Founder & VIP Dinner
Where we are
- Exhibitor Hall opens. Our stand is set up and measuring from the first break.
- Free GlycoCheck™ assessment, about five minutes, results read back with you on the spot.
Thursday October 8, 2026
The day’s headline moment is “The Ultimate Longevity Fireside Chat”, bringing together Aubrey de Grey and Antonio Regalado of MIT Technology Review. Camillo Ricordi, MD opens with a keynote on healthspan engineering to prevent the collapse of reactive health systems, and Anita Goel, MD, PhD explores translating biomarkers of aging into precision longevity medicine — measuring the individual over time.
On the programme
Panels across the tracks, the Exhibitor Hall in full flow and the VIP Night Dinner
Where we are
- The strongest day of the week for us: Anita Goel’s session is about measuring the individual over time, which is the whole argument for a bedside microvascular measure.
- Bring a colleague and be measured together — comparing two readings in the same five minutes is the fastest way to see what the number is telling you.
Friday October 9, 2026
HRH Princess Dr Haya Bint Khaled Bin Bandar Al Saud of Hevolution gives the day’s keynote. A policy panel, “Moving the Needle in Washington”, brings together Randall Rutta of the National Health Council with G. Alexander Fleming, MD and Thomas Seoh of Kitalys, and a further panel examines right-to-try laws in the United States, chaired by Carolyn Baker Ringel.
On the programme
World Stem Cell Summit sessions, clinical implementation, biomarkers & outcomes
Where we are
- Biomarkers & Outcomes is one of the six tracks, and it is the track our instrument belongs to. Come and argue with the methodology — we would rather you did.
Saturday October 10, 2026
Steven A. Garan, PhD leads a panel on women’s health, hormones and healthspan alongside HRH Princess Dr Haya Bint Khaled Bin Bandar Al Saud. Shelly Jordan, MD — a pioneer in regenerative neurology, advanced neuroimaging and brain rejuvenation — delivers a keynote, and a panel on addiction and healthspan is chaired by Marion J. Riggs, PhD.
On the programme
Healthspan Action Coalition forum, the innovation showcase and the Gala Evening Event
Where we are
- Baseline day. If you are measured on Saturday you can be re-measured before the Summit closes — two readings, forty-eight hours apart, is a real demonstration of the method rather than a single number.
Sunday October 11, 2026
Sunday spans regenerative and orthobiologic medicine, vascular health and functional genomics. Paul Tortland, DO brings orthobiologic therapies and Chad Yarbrough, DC covers clinical genetic testing, nutrigenomics and personalised care. Hans Vink, PhD presents his work on the endothelial glycocalyx and the microcirculation — the Summit’s vascular session, and our Premier Sponsor session.
On the programme
Workshops, the closing keynote, partnership signings and the Farewell Reception
Where we are
- Hans Vink, PhD presents. Thirty minutes with time for methodology, results and questions from the room. Time of day to be confirmed by the organisers.
- Last chance to be measured before the Summit closes, and the day to book a re-test if you were measured earlier in the week.
Day summaries are the organiser’s own “At a glance” copy from translationallongevity.com, condensed; the notes on where to find us are ours. A session-by-session agenda has not been published yet — when it is, this page will carry it. Speakers and running order are the organiser’s to change.
Our Premier Sponsor session · Sunday 11 October 2026
Measuring the vessel, not the guess
Longevity medicine has a measurement problem it is honest about: most of what we call biological age is inferred from proxies, and most interventions are judged by whether the proxy moves. The microcirculation offers something less indirect. The endothelial glycocalyx — the gel-like layer lining every blood vessel — can be imaged under the tongue, in the clinic, in about five minutes, without a needle.
Hans will set out what the measurement is, what the published literature does and does not support, and what happens when you re-measure the same person after an intervention. Including the cases where the vascular measure disagrees with the metabolic one.
Hans Vink, PhD — Co-Founder & Director of Advanced Research, Glycocalyx Research Institute; inventor of the GlycoCheck™ measurement
A solo 30-minute session, with time for methodology, results and questions. Session time is set by the organisers and will be confirmed on this page as soon as the detailed agenda is published. GlycoCheck™ is a measurement of microvascular health; it does not diagnose or treat disease.
Hans Vink, PhD
Presenting Sunday 11 October
The session covers
- What the perfused boundary region and the microvascular health score actually measure, and how they are derived from red blood cell dynamics rather than estimated from a questionnaire
- The published evidence that the glycocalyx thins with age in both animals and humans, and what that means for a longevity clinic
- Re-measurement as the point of the exercise: what an intervention looks like when it works, and what it looks like when the weight comes off but the vessel does not improve
- The honest limits — where a single reading has not predicted what people assumed it would, in the largest published cohort to date
- How the measurement is being deployed in clinics, and what a practice needs in order to run it
Who is speaking
Some of the people in the room
The organisers list more than seventy-five speakers across the five days, with keynotes from Camillo Ricordi, David Barzilai, HRH Princess Dr Haya Bint Khaled Bin Bandar Al Saud, Anita Goel, Jeanne Loring, Wei-Wu He, Shelly Jordan and Edward Phillips. A selection, to show the range:
Camillo Ricordi, MD
Keynote · Diabetes Research Institute, University of Miami
Cell transplantation and regenerative medicine; invented the technology for large-scale islet isolation. Author of more than 1,250 publications.
Aubrey de Grey
Chief Science Officer, LEV Foundation
Biomedical gerontologist and one of the defining figures in longevity research. In conversation with MIT Technology Review on the Thursday.
HRH Princess Dr Haya Bint Khaled Bin Bandar Al Saud
Senior Vice President of Research, Hevolution
Keynote on the Friday. Has led national initiatives in genomics and contributed to national committees on biotechnology research.
Anita Goel, MD, PhD
Chairman & Scientific Director, Nanobiosym
Nanobiophysics, and a Harvard lecturer. Speaking on translating biomarkers of aging into precision longevity medicine — measuring the individual over time.
David Barzilai, MD, PhD, DipABLM
Keynote · Harvard Medical School lecturer
Longevity medicine physician and health services researcher working on evidence-based lifestyle medicine and precision diagnostics.
Antonio Regalado
Senior Editor, Biomedicine, MIT Technology Review
Award-winning science and biotechnology journalist, in the Thursday fireside chat.
Jeanne F. Loring, PhD
Professor Emeritus, Scripps Research
Stem cell scientist and a pioneer of regenerative neuroscience; co-founder of Aspen Neuroscience.
Paul Tortland, DO
Founder & Medical Director, New England Stem Cell Institute
Regenerative and sports medicine; on the programme alongside Hans on the Sunday.
Hans Vink, PhD
Co-Founder & Director of Advanced Research, Glycocalyx Research Institute
Endothelial glycocalyx and microcirculation; inventor of GlycoCheck™. Presenting on the Sunday.
Roles are as published by the organisers. The full and current lineup is at translationallongevity.com, where further speakers are still being announced.
Why we are at this Summit
What a translational audience should ask us
This is a meeting about moving things from the bench to the bedside, which means the interesting question about any measurement is not whether it is impressive but what it does and does not support. Five findings from the published literature, including the one that cuts against us.
Vascular aging is measurable, not inferredTrack: Biomarkers & Outcomes
Comparing young and old mice and younger and older adults, glycocalyx thickness in sublingual vessels was 33% lower in the older human participants, with the perfused boundary region 10–22% greater and perfused microvascular density 16–21% lower. The same pattern held across both species. Age shows up in the microcirculation as a number you can take at the chairside.
Source: Machin et al., Am J Physiol Heart Circ Physiol, 2018.
When the scale improves and the vessel does notTrack: Clinical Implementation
In a three-arm randomised controlled trial in 56 adults with type 2 diabetes, a monthly five-day fasting-mimicking diet lowered BMI by 1.0 kg/m² and HbA1c by about 5 mmol/mol — while the dynamic perfused boundary region got 0.32 µm worse, and stayed worse at six-month follow-up. A glycocalyx-targeted supplement arm (Endocalyx, not one of our products) moved the same measure 0.73 µm the other way, with a 0.7-point rise in the microvascular health score. Two interventions, two verdicts, and the metabolic reading alone would have told you the wrong story about one of them.
Re-measurement tracks a real trajectoryTrack: Clinical Implementation
66 treatment-naive adults were measured before starting antiretroviral therapy and again at 24 and 48 weeks. The perfused boundary region fell progressively — 2.17 µm to 2.04 to 1.93 — improving in around two-thirds of individuals, and yet still sat above published healthy-control values at a year. Partial recovery, visible as partial recovery. That is what a biomarker is for.
Source: Fragkou et al., Viruses, 2023.
What the measurement is notTrack: Biomarkers & Outcomes
In the largest study of its kind — 6,169 multi-ethnic adults — a single sublingual reading was independently associated with diabetes, older age and female sex, but was not associated with prevalent cardiovascular disease, coronary heart disease or stroke. A one-off number is not a cardiovascular risk score, and we do not present it as one. Its value is in what it does over time, in the same person, either side of an intervention.
Source: Valerio et al., PLoS One, 2019.
Where the number comes fromMethodology
In 915 middle-aged adults from a population cohort, how deeply red blood cells penetrate the glycocalyx explained about 47% of the variance in perfused boundary region, and tracked inversely with how much of the time a vessel segment actually contained red cells. The measurement is derived from red blood cell dynamics in your own capillaries, not estimated from a questionnaire.
Source: Lee et al., PLoS One, 2014.
Each of these is a published study in our research library, linked in full. GlycoCheck™ is a measurement of microvascular health; it does not diagnose or treat disease, and the supplement arm of the 2024 randomised trial above tested Endocalyx, not one of our products.
The science
The endothelial glycocalyx: the foundation of vascular health
The glycocalyx is the fragile gel layer lining every blood vessel in your body. When it degrades, delivery fails in the microvessels first — long before a standard test finds anything. GlycoCheck images that layer directly and scores it.
Our clinical workflow
Measure • Restore • Verify
Three steps that turn vascular health from something you infer into something you can show a patient.
Measure
GlycoCheck™ System FDA Class I Registered
Use the GlycoCheck™ System to objectively assess endothelial glycocalyx and microvascular health through a simple, non-invasive assessment performed under the tongue in under five minutes.
- Objectively evaluates endothelial glycocalyx and microvascular health
- Detects early microvascular dysfunction
- Establishes a personalized baseline
- Provides objective measurements to help guide clinical decisions
- Generates a MicroVascular Health Score™ (MVHS)
Restore
What Do You Do Once You Identify Dysfunction?
ReVasca™Endothelial Glycocalyx Support
Develop personalized strategies designed to support endothelial glycocalyx and microvascular health.
- ReVasca™
- Lifestyle
- Nutrition
- Exercise
- Risk-factor reduction
- Physician-directed integrative therapies
Verify
Objective OutcomesRepeat. Compare. Improve.
Low MVHS Score2.36
High MVHS Score18.71
MicroVascular Health Score before and after 12 weeks taking ReVasca™.Individual results may vary.
Repeat GlycoCheck™ assessments to:
- Measure changes against baseline
- Guide clinical decisions
- Document treatment effectiveness
- Evaluate treatment response
- Improve patient communication and outcomes
Real Measurements. Clear, Actionable Insights.
See the published researchTested in under five minutes
A complete microvascular health evaluation, performed non-invasively under the tongue at our stand — then a few more minutes to review and understand your own results. No needles, no blood draw, no waiting for a lab.
At the conference
Visit our stand
Come and be measured. It is the fastest way to understand what GlycoCheck does — and what it would do in your own practice.
- Experience a live GlycoCheck™ assessment, about five minutes, no preparation
- See a complete microvascular health evaluation performed on the spot
- Review your own microvascular health score with the team
- Be measured early in the week and re-measured before it closes
- Discuss the published methodology, and where it does not hold
- Explore research collaboration and institutional deployment
The wider programme
The Summit is the closing conference of Boston Longevity Week
From 1 to 11 October, Boston Longevity Week gathers longevity researchers, clinicians and investors across the city around three anchor conferences. They run in a deliberate order — the molecular biology, then the measurement, then the clinic. The Translational Longevity Summit is the third, and the one we are at.
ARDD 2026
Aging Research & Drug Discovery — the premier scientific meeting on the molecular biology of aging.
Rubenstein Treehouse, HarvardBiomarkers of Aging
Building standardised, clinically validated ways to measure aging and assess intervention outcomes.
Harvard Medical SchoolTranslational Longevity Summit
Where the week’s science meets the clinic, translating breakthroughs into real-world patient outcomes. This is the one we are at.
1 Milestone Place, Harvard ERCPlus symposia and satellite gatherings across the eleven days. Full week programme at bostonlongevityweek.com; our page for the week is at Boston Longevity Week 2026.
The venue
1 Milestone Place, Harvard Enterprise Research Campus
One Milestone is Harvard’s flagship Enterprise Research Campus in Allston: a life-science and innovation building with an auditorium, flexible event floors and collaboration commons, which is why the Summit can run plenaries and small workshops in the same place on the same day. The adjacent Atlas Hotel provides accommodation on site. Ask us about room availability if you are coming in from out of town — the organisers can help.
The six scientific tracks
Patient Advocacy
Centring the patient experience and giving advocates a platform to shape research priorities, policy and clinical standards.
Clinical Implementation
Practical protocols and frameworks helping practitioners integrate longevity science into patient care today.
Translational Science
Cellular therapies, tissue regeneration and stem cell science moving from lab to clinical application.
Biomarkers & Outcomes
Defining biological markers that predict healthspan and guide precision longevity protocols. This is our track.
Policy, Access & Equity
Policy pathways and systemic conversations that democratise access to longevity medicine.
Innovation & Collaboration
Where startups, institutions, investors and innovators converge to build the longevity economy.
Registration
On-site passes include sessions, meals and materials for the days selected; accommodation is not included. Prices are the organiser’s and were correct on 17 September 2026 — check before booking.
Professionals
$1,197Clinicians · researchers · industry
- Full five-day access to every track
- Keynotes, workshops and networking events
- Certificate of participation
- Summit bag, meals and materials
Flexi-Pass
$497Up to three days of your choice
- Any three days, sessions across every track
- Certificate of participation
- Meals and materials on attended days
- Day selection made at registration
Students
$197Full-time students, valid ID required
- Full five-day access to every track
- Keynote and workshop access
- Certificate of participation
- Summit bag, meals and materials
Registration, payment and any changes are handled entirely by Boston BioLife at translationallongevity.com — we are a sponsor, not the organiser. Sponsorship enquiries go to Joseph Krieger, President & Founder of Boston BioLife.
Meet the founders
The science and the technology, in one room
One of the unique opportunities at the Summit is the chance to meet the founders behind both. Ask questions directly, and discuss the science and its practical implementation.
Dr Hans Vink, PhD
Co-Founder & Chief Science Officer
Internationally recognised vascular scientist and a pioneer of endothelial glycocalyx research. Hans has spent more than two decades advancing our understanding of the glycocalyx and its role in microvascular health — work behind more than 160 peer-reviewed publications, validated by over 300 medical and research institutions worldwide.
Robert (Bob) Long
Co-Founder & Chief Executive Officer
For more than 15 years Bob has worked alongside Hans to turn glycocalyx science from academic research into practical clinical tools — helping physicians, researchers and healthcare organisations implement GlycoCheck™ and build a category of medicine centred on objective measurement of vascular health.
Together, Hans and Bob have spent more than fifteen years building GlycoCheck™, ReVasca™ and the Glycocalyx Research Institute into one of the world’s leading organisations dedicated to endothelial glycocalyx research, education and clinical implementation.
For conference attendees
Conference specials
Available to the Translational Longevity Summit attendees. Come to the stand and mention the conference.
GlycoCheck™
- Complimentary consultation
- Live system demonstration
- Conference-only pricing and promotional package
- Practice implementation consultation
- Follow-up strategy session after the conference
ReVasca™
- Conference pricing on practitioner starter packages
- Introductory subscription offer for attendees
- Practitioner enrolment information
- Patient education materials
- Conference bundle opportunities
Exact offers are confirmed closer to the conference. Ask at the stand for the current package, or get in touch beforehand.
Take it with you
Conference resources
Download before you come, or scan at the stand.
The conference
About the Translational Longevity Summit
The Translational Longevity Summit is produced under the Boston BioLife umbrella with the Healthspan Action Coalition, the World Stem Cell Summit and the Regenerative Medicine Foundation, and it runs at 1 Milestone Place on Harvard’s Enterprise Research Campus from 7 to 11 October. Six scientific tracks, more than seventy-five speakers, and a format built so you can take one day, three, or all five.
Its stated frame is the gap between discovery and deployment: what actually reaches a patient. That makes it an unusually demanding room for anyone selling a measurement, which is precisely why we took the Premier level — it comes with a session on the programme rather than a louder booth.
Who attends: Clinicians and practitioners implementing longevity protocols, academic and industry researchers, patients and advocates, and the biotech founders, investors and policymakers around them. Evidence-first — this audience reads the papers.
Produced by: Boston BioLife & the Healthspan Action Coalition
With: the World Stem Cell Summit and the Regenerative Medicine Foundation
Host: Joseph Krieger, President & Founder, Boston BioLife
Part of: Boston Longevity Week 2026, October 1–11
Our level: Premier Sponsor
Venue: 1 Milestone Place, Harvard Enterprise Research Campus, Allston
Dates: October 7–11, 2026
Why we are there
- GlycoCheck™ is a functional biomarker of vascular aging taken at the chairside in about five minutes, not a questionnaire and not an estimate.
- A Biomarkers & Outcomes track exists at this Summit because the field has agreed that claims about aging are only as good as the instruments behind them.
- Hans Vink presents the methodology and its published limits — including the largest study, which found a single reading does not track prevalent cardiovascular disease.
- ReVasca™ is presented as what the measurement led to, in that order, never the reverse.
Before you come
Frequently asked
When and where is the Translational Longevity Summit?
When does Hans Vink speak?
Do I need a full five-day ticket to be measured?
What does being Premier Sponsor mean for me as an attendee?
Where is your booth?
What is GlycoCheck™?
How long does the assessment take?
Does it hurt, and is it invasive?
What is ReVasca™?
How do I become a practitioner or bring GlycoCheck™ into my practice?
Can I schedule a demonstration or a private meeting?
Where can I find the published research?
Reserve time with us at the Translational Longevity Summit
Exhibition floors are busy. Book a slot and we will hold it — for a demonstration, an implementation conversation, or simply to be measured properly.